Nanoplasmonic Biosensor for Label-Free miRNA Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting miRNAs as disease markers in blood are limited by low sensitivity and selectivity, requiring label-based techniques and complex pre-processing steps, which are costly and prone to errors due to chemical modifications and environmental factors.
Innovation Solution
A label-free nanoplasmonic biosensor using gold nanopillars and DNA or LNA probes that amplify Raman signals upon miRNA binding, enabling multiplex detection of miRNAs such as miR-10b, miR-21, miR-373, and miR-200C with high selectivity and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If label-based detection methods are used for miRNA detection, then sensitivity can be improved, but device complexity and cost increase due to requiring fluorescent materials and complex pre-processing steps
Solution Approach 1:
The invention extracts and eliminates the labeling step from the detection system. By using label-free detection with Raman spectroscopy, the method removes the need for fluorescent materials and complex pre-processing steps while maintaining detection capability through direct detection of miRNA-RNA hybrid structures.
Solution Approach 2:
The invention replaces the optical/chemical labeling system with a Raman spectroscopy-based detection system. This substitution eliminates the need for fluorescent labels and complex pre-processing by directly detecting the vibrational modes of the miRNA molecules bound to the sensor surface.
2Measurement precision
If conventional biomarkers are used for cancer detection, then detection can be performed at disease onset, but detection at early and metastatic stages becomes difficult due to insufficient sample collection
Solution Approach 1:
The invention changes the detection parameter from conventional biomarkers to circulating miRNAs, which are present in blood at detectable levels even at early cancer stages. This parameter change enables effective detection when sample amounts are limited, as miRNAs can be reliably detected in small blood volumes using the highly sensitive Raman-based sensor.
3Adaptability or versatility
If multiple miRNAs are detected simultaneously, then diagnostic information increases, but detection selectivity decreases due to cross-reactivity in multiplex systems
Solution Approach 1:
The invention segments the detection system into multiple independent sensing zones, each functionalized with a specific capture probe for a different miRNA target. This spatial segmentation allows simultaneous detection of multiple miRNAs without cross-reactivity, as each zone operates independently with its own specificity.
Solution Approach 2:
The invention applies local quality by functionalizing different regions of the sensor surface with different capture probes having specific sequences complementary to different miRNAs. Each local region has optimized specificity for its target, enabling multiplex detection while maintaining high selectivity through localized probe-miRNA interactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biosensor achieves effective label-free multiplex detection of miRNAs in blood with high sensitivity and selectivity, reducing costs and complexity, and is suitable for clinical applications in diagnosing miRNA-related diseases.
Implementation Method 1
a plurality of gold nanopillars formed by coating gold particles on the protrusions and in the form of thin films surrounding the protrusions
Data Source
AI summary
The present invention relates to a nanoplasmonic biosensor capable of label-free multiplex detection of disease markers in blood with high selectivity and sensitivity and a method for detecting disease markers using the nanoplasmonic biosensor. The nanoplasmonic biosensor of the present invention enables label-free multiplex detection of miRNAs as disease markers in blood with high selectivity and sensitivity. Therefore, the nanoplasmonic biosensor of the present invention can be effectively used for the diagnosis of miRNA-related diseases and clinical applications.